<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28935773</article-id><article-id pub-id-type="pmc">5728028</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0066</article-id><article-id pub-id-type="publisher-id">ONCO12239</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>5</subject><subject>31</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>A Randomized, Double&#x02010;Blinded, Phase II Trial of Gemcitabine and Nab&#x02010;Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial</article-title></title-group><contrib-group><contrib id="onco12239-cr-0001" contrib-type="author" corresp="yes"><name><surname>Ko</surname><given-names>Andrew H.</given-names></name><address><email>andrew.ko@ucsf.edu</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12239-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12239-cr-0002" contrib-type="author"><name><surname>Murphy</surname><given-names>Patrick B.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12239-cr-0003" contrib-type="author"><name><surname>Peyton</surname><given-names>James D.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12239-cr-0004" contrib-type="author"><name><surname>Shipley</surname><given-names>Dianna L.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12239-cr-0005" contrib-type="author"><name><surname>Al&#x02010;Hazzouri</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="onco12239-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12239-cr-0006" contrib-type="author"><name><surname>Rodriguez</surname><given-names>Francisco A.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12239-cr-0007" contrib-type="author"><name><surname>Womack</surname><given-names>Mark S.</given-names><suffix>IV</suffix></name><xref ref-type="aff" rid="onco12239-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12239-cr-0008" contrib-type="author"><name><surname>Xiong</surname><given-names>Henry Q.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12239-cr-0009" contrib-type="author"><name><surname>Waterhouse</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0006"><sup>f</sup></xref></contrib><contrib id="onco12239-cr-00010" contrib-type="author"><name><surname>Tempero</surname><given-names>Margaret A.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12239-cr-00011" contrib-type="author"><name><surname>Guo</surname><given-names>Shuangli</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00012" contrib-type="author"><name><surname>Lane</surname><given-names>Cassie M.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00013" contrib-type="author"><name><surname>Earwood</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00014" contrib-type="author"><name><surname>DeBusk</surname><given-names>Laura M.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00015" contrib-type="author"><name><surname>Bendell</surname><given-names>Johanna C.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><aff id="onco12239-aff-0001"><label><sup>a</sup></label>
<institution>Division of Hematology and Oncology, University of California</institution>, <city>San Francisco</city>, <state>California</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0002"><label><sup>b</sup></label>
<institution>Tennessee Oncology, PLLC/SCRI</institution>, <city>Nashville</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0003"><label><sup>c</sup></label><institution>Florida Cancer Specialists/SCRI</institution>, <city>Fort Myers</city>, <state>Florida</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0004"><label><sup>d</sup></label>
<institution>Tennessee Oncology, PLLC/SCRI</institution>, <city>Chattanooga</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0005"><label><sup>e</sup></label><institution>The Center for Cancer and Blood Disorders/SCRI</institution>, <city>Fort Worth</city>, <state>Texas</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0006"><label><sup>f</sup></label><institution>Oncology Hematology Care/SCRI</institution>, <city>Cincinnati</city>, <state>Ohio</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0007"><label><sup>g</sup></label><institution>Sarah Cannon Research Institute (SCRI)</institution>, <city>Nashville</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Andrew Ko, M.D., Division of Hematology and Oncology, University of California, San Francisco, 550 16th Street, Box 3211, San Francisco, California 94143, USA. Telephone: 415&#x02010;353&#x02010;7286; e&#x02010;mail: <email>andrew.ko@ucsf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>9</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/onco.v22.12</issue-id><fpage>1427</fpage><lpage>e129</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">&#x000a9; AlphaMed Press; the data published online to support this summary is the property of the authors</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12239.pdf"/><abstract><title>Abstract</title><sec id="onco12239-sec-1001"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12239-list-0002"><list-item id="onco12239-li-0005"><p>The addition of the heat shock protein 27 (Hsp27)&#x02010;targeting antisense oligonucleotide, apatorsen, to a standard first&#x02010;line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer.</p></list-item><list-item id="onco12239-li-0006"><p>Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.</p></list-item></list></p></sec><sec id="onco12239-sec-1202"><title>Background.</title><p>This randomized, double&#x02010;blinded, phase II trial evaluated the efficacy of gemcitabine/nab&#x02010;paclitaxel plus either apatorsen, an antisense oligonucleotide targeting heat shock protein 27 (Hsp27) mRNA, or placebo in patients with metastatic pancreatic cancer.</p></sec><sec id="onco12239-sec-1102"><title>Methods.</title><p>Patients were randomized 1:1 to Arm A (gemcitabine/nab&#x02010;paclitaxel plus apatorsen) or Arm B (gemcitabine/nab&#x02010;paclitaxel plus placebo). Treatment was administered in 28&#x02010;day cycles, with restaging every 2 cycles, until progression or intolerable toxicity. Serum Hsp27 levels were analyzed at baseline and on treatment. The primary endpoint was overall survival (OS).</p></sec><sec id="onco12239-sec-1101"><title>Results.</title><p>One hundred thirty&#x02010;two patients were enrolled, 66 per arm. Cytopenias and fatigue were the most frequent grade 3/4 treatment&#x02010;related adverse events for both arms. Median progression&#x02010;free survival (PFS) and OS were 2.7 and 5.3 months, respectively, for arm A, and 3.8 and 6.9 months, respectively, for arm B. Objective response rate was 18% for both arms. Patients with high serum level of Hsp27 represented a poor&#x02010;prognosis subgroup who may have derived modest benefit from addition of apatorsen.</p></sec><sec id="onco12239-sec-1111"><title>Conclusion.</title><p>Addition of apatorsen to chemotherapy does not improve outcomes in unselected patients with metastatic pancreatic cancer in the first&#x02010;line setting, although a trend toward prolonged PFS and OS in patients with high baseline serum Hsp27 suggests this therapy may warrant further evaluation in this subgroup.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh"><bold>&#x07ecf;&#x09a8c;&#x0603b;&#x07ed3;</bold></p><p xml:lang="zh">&#x02022; &#x05728;&#x0975e;&#x07ecf;&#x09009;&#x08f6c;&#x079fb;&#x06027;&#x080f0;&#x0817a;&#x0764c;&#x060a3;&#x08005;&#x07684;&#x06807;&#x051c6;&#x04e00;&#x07ebf;&#x05316;&#x07597;&#x065b9;&#x06848;&#x04e2d;&#x06dfb;&#x052a0;&#x09776;&#x05411;&#x070ed;&#x04f11;&#x0514b;&#x086cb;&#x0767d;27 (Hsp27) &#x07684;&#x053cd;&#x04e49;&#x05be1;&#x06838;&#x082f7;&#x09178;apatorsen&#x04e0d;&#x04f1a;&#x05ef6;&#x0957f;&#x0751f;&#x05b58;&#x0671f;&#x03002;</p><p xml:lang="zh">&#x02022;&#x0672c;&#x08bd5;&#x09a8c;&#x07684;&#x07ed3;&#x0679c;&#x063d0;&#x0793a;&#x08840;&#x06e05;Hsp27&#x053ef;&#x080fd;&#x05177;&#x06709;&#x09884;&#x0540e;&#x0548c;&#x09884;&#x06d4b;&#x04ef7;&#x0503c;, &#x04f46;&#x09700;&#x08fdb;&#x0884c;&#x08fdb;&#x04e00;&#x06b65;&#x07814;&#x07a76;&#x03002;</p><p xml:lang="zh"><bold>&#x06458;&#x08981;</bold></p><p xml:lang="zh"><bold><italic>&#x080cc;&#x0666f;</italic>.</bold>&#x0672c;&#x09879;&#x0968f;&#x0673a;&#x03001;&#x053cc;&#x076f2;&#x03001;II&#x0671f;&#x08bd5;&#x09a8c;&#x08bc4;&#x04ef7;&#x04e86;&#x05409;&#x0897f;&#x04ed6;&#x06ee8;/&#x0767d;&#x086cb;&#x0767d;&#x07ed3;&#x05408;&#x0578b;&#x07d2b;&#x06749;&#x09187;&#x08054;&#x05408;apatorsen[&#x09776;&#x05411;&#x070ed;&#x04f11;&#x0514b;&#x086cb;&#x0767d;27 (Hsp27) mRNA&#x07684;&#x053cd;&#x04e49;&#x05be1;&#x06838;&#x082f7;&#x09178;]&#x06216;&#x05b89;&#x06170;&#x05242;&#x06cbb;&#x07597;&#x08f6c;&#x079fb;&#x06027;&#x080f0;&#x0817a;&#x0764c;&#x060a3;&#x08005;&#x07684;&#x06548;&#x0679c;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x065b9;&#x06cd5;</italic>.</bold>&#x060a3;&#x08005;&#x06309;1:1&#x07684;&#x06bd4;&#x04f8b;&#x088ab;&#x0968f;&#x0673a;&#x05206;&#x0914d;&#x08fdb;&#x05165;A&#x07ec4;&#x0ff08;&#x05409;&#x0897f;&#x04ed6;&#x06ee8;/&#x0767d;&#x086cb;&#x0767d;&#x07ed3;&#x05408;&#x0578b;&#x07d2b;&#x06749;&#x09187;&#x08054;&#x05408;apatorsen&#x0ff09;&#x06216;B&#x07ec4;&#x0ff08;&#x05409;&#x0897f;&#x04ed6;&#x06ee8;/&#x0767d;&#x086cb;&#x0767d;&#x07ed3;&#x05408;&#x0578b;&#x07d2b;&#x06749;&#x09187;&#x08054;&#x05408;&#x05b89;&#x06170;&#x05242;&#x0ff09;&#x03002;&#x06cbb;&#x07597;&#x05468;&#x0671f;&#x04e3a;28&#x05929;, &#x06bcf;2&#x04e2a;&#x05468;&#x0671f;&#x05bf9;&#x075be;&#x075c5;&#x08fdb;&#x0884c;&#x04e00;&#x06b21;&#x091cd;&#x065b0;&#x05206;&#x0671f;, &#x076f4;&#x081f3;&#x051fa;&#x073b0;&#x075be;&#x075c5;&#x08fdb;&#x05c55;&#x06216;&#x04e0d;&#x053ef;&#x08010;&#x053d7;&#x07684;&#x06bd2;&#x06027;&#x03002;&#x05728;&#x057fa;&#x07ebf;&#x0671f;&#x0548c;&#x06cbb;&#x07597;&#x0671f;&#x095f4;&#x05206;&#x06790;&#x04e86;&#x08840;&#x06e05;Hsp27&#x06c34;&#x05e73;&#x03002;&#x04e3b;&#x08981;&#x07ec8;&#x070b9;&#x04e3a;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;OS&#x0ff09;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x0679c;</italic>.</bold>&#x05171;&#x05165;&#x07ec4;&#x04e86;132&#x04f8b;&#x060a3;&#x08005;, &#x06bcf;&#x07ec4;66&#x04f8b;&#x03002;&#x08840;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x0548c;&#x075b2;&#x04e4f;&#x0662f;&#x04e24;&#x07ec4;&#x04e2d;&#x06700;&#x05e38;&#x089c1;&#x07684;3/4&#x07ea7;&#x06cbb;&#x07597;&#x076f8;&#x05173;&#x04e0d;&#x0826f;&#x04e8b;&#x04ef6;&#x03002;A&#x07ec4;&#x07684;&#x04e2d;&#x04f4d;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;PFS&#x0ff09;&#x0548c;OS&#x05206;&#x0522b;&#x04e3a;2.7&#x0548c;5.3&#x04e2a;&#x06708;&#x0ff1b;B&#x07ec4;&#x05206;&#x0522b;&#x04e3a;3.8&#x0548c;6.9&#x04e2a;&#x06708;&#x03002;&#x04e24;&#x07ec4;&#x07684;&#x05ba2;&#x089c2;&#x07f13;&#x089e3;&#x07387;&#x05747;&#x04e3a;18%&#x03002;Hsp27&#x08840;&#x06e05;&#x06c34;&#x05e73;&#x08f83;&#x09ad8;&#x07684;&#x060a3;&#x08005;&#x04ee3;&#x08868;&#x053ef;&#x080fd;&#x05df2;&#x07ecf;&#x04ece;&#x06dfb;&#x052a0;apatorsen&#x04e2d;&#x09002;&#x05ea6;&#x083b7;&#x076ca;&#x07684;&#x09884;&#x0540e;&#x04e0d;&#x04f73;&#x04e9a;&#x07ec4;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x08bba;</italic>.</bold>&#x05728;&#x0975e;&#x07ecf;&#x09009;&#x08f6c;&#x079fb;&#x06027;&#x080f0;&#x0817a;&#x0764c;&#x060a3;&#x08005;&#x07684;&#x04e00;&#x07ebf;&#x05316;&#x07597;&#x04e2d;&#x06dfb;&#x052a0;apatorsen&#x04e0d;&#x04f1a;&#x06539;&#x05584;&#x06cbb;&#x07597;&#x07ed3;&#x05c40;, &#x04f46;&#x057fa;&#x07ebf;&#x0671f;&#x08840;&#x06e05;Hsp27&#x06c34;&#x05e73;&#x08f83;&#x09ad8;&#x060a3;&#x08005;&#x07684;PFS&#x0548c;OS&#x05ef6;&#x0957f;&#x07684;&#x08d8b;&#x052bf;&#x08868;&#x0660e;&#x053ef;&#x080fd;&#x09700;&#x05728;&#x08be5;&#x04e9a;&#x07ec4;&#x04e2d;&#x05bf9;&#x08fd9;&#x04e00;&#x07597;&#x06cd5;&#x08fdb;&#x0884c;&#x08fdb;&#x04e00;&#x06b65;&#x07814;&#x07a76;&#x03002;</p></trans-abstract><counts><page-count count="15"/></counts></article-meta></front><body><sec sec-type="discussion" id="onco12239-sec-0005"><title>Discussion</title><p>Heat shock protein 27 (Hsp27) is a protein chaperone whose expression is induced by cytotoxic chemotherapy, as well as other cell stressors such as hyperthermia, oxidative stress, and radiation, resulting in cytoprotection against these insults [<xref rid="onco12239-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12239-bib-0002" ref-type="ref">2</xref>]. Various malignancies, including pancreatic adenocarcinoma, overexpress Hsp27 [3]; furthermore, preclinical studies show that Hsp27 expression may play a role in the resistance of pancreatic cancer cell lines to gemcitabine [<xref rid="onco12239-bib-0004" ref-type="ref">4</xref>], [<xref rid="onco12239-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12239-bib-0006" ref-type="ref">6</xref>]. Thus, inhibiting Hsp27 activity represents a viable therapeutic strategy in this disease. Apatorsen, an antisense oligonucleotide designed to bind to Hsp27 mRNA and block its translation into functional protein, offers one such approach [<xref rid="onco12239-bib-0007" ref-type="ref">7</xref>].</p><p>On these bases, we performed a randomized phase II trial to compare the safety and efficacy of gemcitabine and nab&#x02010;paclitaxel in combination with either apatorsen or placebo in the first&#x02010;line setting for patients with metastatic pancreatic cancer. The planned sample size of 130 provided 80% power to detect a difference in median survival of 8.5 versus 13.4 months (hazard ratio [HR] for death, 0.634; 1&#x02010;sided a&#x02009;=&#x02009;0.1).</p><table-wrap id="onco12239-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Median PFS and OS stratified by heat shock protein 27 levels</title></caption><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12239-note-0002"><p>Abbreviations: CI, confidence interval; Hsp27, heat shock protein 27; OS, overall survival; PFS, progression&#x02010;free survival.</p></fn></table-wrap-foot></table-wrap><p>Although the incidence of toxicities did not differ significantly between the two treatment arms (most common treatment&#x02010;related toxicities of all grades on both arms included fatigue, cytopenias, and gastrointestinal symptoms), the addition of apatorsen to chemotherapy did not produce any improvement in clinical outcomes in the intent&#x02010;to&#x02010;treat population. The objective response rate (ORR) was identical (18%) on both treatment arms, whereas patients on the apatorsen arm fared numerically worse in terms of both progression&#x02010;free survival (PFS) and overall survival (OS) when compared with patients on the placebo arm, although these differences were not statistically significant (median PFS, 2.7 vs. 3.8 months, respectively [<italic>p</italic>&#x02009;=&#x02009;.92; HR 1.0]; median OS, 5.3 vs. 6.9 months, respectively [<italic>p</italic>&#x02009;=&#x02009;.62; HR 1.1]). Notably, the survival outcomes for patients on both arms of this study were considerably inferior to those observed on the gemcitabine/nab&#x02010;paclitaxel arm from the phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study [<xref rid="onco12239-bib-0008" ref-type="ref">8</xref>], for unclear reasons.</p><p>The only subgroup for whom a potential benefit of apatorsen could be identified was those patients with high serum levels of Hsp27, a marker associated with a very poor prognosis overall (median PFS for patients with high baseline serum Hsp27 levels, 3.3 vs. 0.9 months for apatorsen vs. placebo, respectively [HR 0.38], median OS 3.3 vs. 1.0 months [HR 0.59]). However, the number of subjects who fit into this category was too small, representing only 14% of the entire study population, to draw any definitive conclusions.</p><p>In summary, the addition of apatorsen to a standard combination chemotherapy regimen in the first&#x02010;line setting did not result in improvement in survival or other clinically relevant endpoints in patients with metastatic pancreatic cancer. Although further studies of this agent in unselected patients do not appear to be indicated, the findings from this trial do hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.</p></sec><sec id="onco12239-sec-0006"><title>Trial Information</title><p>
<def-list id="onco12239-lp-0001"><def-item><term id="onco12239-li-0007">Disease</term><def id="onco12239-li-0008"><p>Metastatic pancreatic adenocarcinoma</p></def></def-item><def-item><term id="onco12239-li-0009">Stage of Disease/Treatment</term><def id="onco12239-li-0010"><p>Metastatic/advanced</p></def></def-item><def-item><term id="onco12239-li-0011">Prior Therapy</term><def id="onco12239-li-0012"><p>None</p></def></def-item><def-item><term id="onco12239-li-0013">Type of Study &#x02013; 1</term><def id="onco12239-li-0014"><p>Phase II</p></def></def-item><def-item><term id="onco12239-li-0015">Type of Study &#x02013; 2</term><def id="onco12239-li-0016"><p>Randomized</p></def></def-item><def-item><term id="onco12239-li-0019">PFS</term><def id="onco12239-li-0020"><p><italic>p</italic>&#x02009;=&#x02009;0.92, HR: 1.0</p></def></def-item><def-item><term id="onco12239-li-0021">OS</term><def id="onco12239-li-0022"><p><italic>p</italic>&#x02009;=&#x02009;0.62, HR: 1.1</p></def></def-item><def-item><term id="onco12239-li-0025">Primary Endpoint</term><def id="onco12239-li-0026"><p>Overall survival</p></def></def-item><def-item><term id="onco12239-li-0027">Secondary Endpoint</term><def id="onco12239-li-0028"><p>Progression&#x02010;free survival</p></def></def-item><def-item><term id="onco12239-li-0029">Secondary Endpoint</term><def id="onco12239-li-0030"><p>Toxicity</p></def></def-item><def-item><term id="onco12239-li-0031">Investigator's Analysis</term><def id="onco12239-li-0032"><p>Feasible, possibly effective in patients with high Hsp27 serum levels</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0007"><title>Drug Information for Phase II Control</title><p>
<def-list id="onco12239-lp-0002"><def-item><term id="onco12239-li-0033">Drug 1</term><def id="onco12239-li-0034"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0035">Generic/Working name</term><def id="onco12239-li-0036"><p>Nab&#x02010;paclitaxel</p></def></def-item><def-item><term id="onco12239-li-0037">Trade name</term><def id="onco12239-li-0038"><p>Abraxane</p></def></def-item><def-item><term id="onco12239-li-0039">Company name</term><def id="onco12239-li-0040"><p>Celgene</p></def></def-item><def-item><term id="onco12239-li-0041">Drug type</term><def id="onco12239-li-0042"><p>Other</p></def></def-item><def-item><term id="onco12239-li-0043">Drug class</term><def id="onco12239-li-0044"><p>Microtubule&#x02010;targeting agent</p></def></def-item><def-item><term id="onco12239-li-0045">Dose</term><def id="onco12239-li-0046"><p>125 milligrams (mg) per square meter (m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12239-li-0047">Route</term><def id="onco12239-li-0048"><p>IV</p></def></def-item><def-item><term id="onco12239-li-0049">Schedule of administration</term><def id="onco12239-li-0050"><p>Placebo days 1, 8, 15, and 22 of a 28&#x02010;day cycle Nab&#x02010;paclitaxel and gemcitabine days 1, 8, and 15 of a 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12239-li-0053">Drug 2</term><def id="onco12239-li-0054"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0055">Generic/Working name</term><def id="onco12239-li-0056"><p>Gemcitabine</p></def></def-item><def-item><term id="onco12239-li-0057">Trade name</term><def id="onco12239-li-0058"><p>Gemzar</p></def></def-item><def-item><term id="onco12239-li-0059">Company name</term><def id="onco12239-li-0060"><p>Eli Lilly</p></def></def-item><def-item><term id="onco12239-li-0061">Drug type</term><def id="onco12239-li-0062"><p>Other</p></def></def-item><def-item><term id="onco12239-li-0063">Drug class</term><def id="onco12239-li-0064"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12239-li-0065">Dose</term><def id="onco12239-li-0066"><p>1,000 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12239-li-0067">Route</term><def id="onco12239-li-0068"><p>IV</p></def></def-item><def-item><term id="onco12239-li-0069">Schedule of administration</term><def id="onco12239-li-0070"><p>Placebo days 1, 8, 15, and 22 of a 28&#x02010;day cycle Nab&#x02010;paclitaxel and gemcitabine days 1, 8, and 15 of a 28&#x02010;day cycle</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0008"><title>Drug Information for Phase II Experimental</title><p>
<def-list id="onco12239-lp-0003"><def-item><term id="onco12239-li-0073">Drug 1</term><def id="onco12239-li-0074"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0075">Generic/Working name</term><def id="onco12239-li-0076"><p>Apatorsen</p></def></def-item><def-item><term id="onco12239-li-0077">Trade name</term><def id="onco12239-li-0078"><p>Not applicable</p></def></def-item><def-item><term id="onco12239-li-0079">Company name</term><def id="onco12239-li-0080"><p>OncoGenex</p></def></def-item><def-item><term id="onco12239-li-0081">Drug type</term><def id="onco12239-li-0082"><p>Other</p></def></def-item><def-item><term id="onco12239-li-0083">Drug class</term><def id="onco12239-li-0084"><p>Antisense oligonucleotide</p></def></def-item><def-item><term id="onco12239-li-0085">Dose</term><def id="onco12239-li-0086"><p>600 mg per flat dose</p></def></def-item><def-item><term id="onco12239-li-0087">Route</term><def id="onco12239-li-0088"><p>IV</p></def></def-item><def-item><term id="onco12239-li-0089">Schedule of administration</term><def id="onco12239-li-0090"><p>Apatorsen days 1, 8, 15, and 22 of a 28&#x02010;day cycle Nab&#x02010;paclitaxel and gemcitabine days 1, 8, and 15 of a 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12239-li-0093">Drug 2</term><def id="onco12239-li-0094"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0095">Generic/Working name</term><def id="onco12239-li-0096"><p>Nab&#x02010;paclitaxel</p></def></def-item><def-item><term id="onco12239-li-0097">Trade name</term><def id="onco12239-li-0098"><p>Abraxane</p></def></def-item><def-item><term id="onco12239-li-0099">Company name</term><def id="onco12239-li-0100"><p>Celgene</p></def></def-item><def-item><term id="onco12239-li-0101">Drug type</term><def id="onco12239-li-0102"><p>Other</p></def></def-item><def-item><term id="onco12239-li-0103">Drug class</term><def id="onco12239-li-0104"><p>Microtubule&#x02010;targeting agent</p></def></def-item><def-item><term id="onco12239-li-0105">Dose</term><def id="onco12239-li-0106"><p>125 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12239-li-0107">Schedule of administration</term><def id="onco12239-li-0108"><p>Apatorsen days 1, 8, 15, and 22 of a 28&#x02010;day cycle Nab&#x02010;paclitaxel and gemcitabine days 1, 8, and 15 of a 28&#x02010;day cycle pfof</p></def></def-item><def-item><term id="onco12239-li-0111">Drug 3</term><def id="onco12239-li-0112"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0113">Generic/Working name</term><def id="onco12239-li-0114"><p>Gemcitabine</p></def></def-item><def-item><term id="onco12239-li-0115">Trade name</term><def id="onco12239-li-0116"><p>Gemzar</p></def></def-item><def-item><term id="onco12239-li-0117">Company name</term><def id="onco12239-li-0118"><p>Eli Lilly</p></def></def-item><def-item><term id="onco12239-li-0119">Drug type</term><def id="onco12239-li-0120"><p>Other</p></def></def-item><def-item><term id="onco12239-li-0121">Drug class</term><def id="onco12239-li-0122"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12239-li-0123">Dose</term><def id="onco12239-li-0124"><p>1,000 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12239-li-0125">Route</term><def id="onco12239-li-0126"><p>IV</p></def></def-item><def-item><term id="onco12239-li-0127">Schedule of administration</term><def id="onco12239-li-0128"><p>Apatorsen 1, 8, 15, and 22 of a 28&#x02010;day cycle Nab&#x02010;paclitaxel and gemcitabine days 1, 8, and 15 of a 28&#x02010;day cycle</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0009"><title>Patient Characteristics for Phase II Control</title><p>
<def-list id="onco12239-lp-0004"><def-item><term id="onco12239-li-0131">Number of Patients, Male</term><def id="onco12239-li-0132"><p>38</p></def></def-item><def-item><term id="onco12239-li-0133">Number of Patients, Female</term><def id="onco12239-li-0134"><p>28</p></def></def-item><def-item><term id="onco12239-li-0135">Stage</term><def id="onco12239-li-0136"><p>IV</p></def></def-item><def-item><term id="onco12239-li-0137">Age</term><def id="onco12239-li-0138"><p>Median (range): 65.5 (47&#x02013;83)</p></def></def-item><def-item><term id="onco12239-li-0139">Number of Prior Systemic Therapies</term><def id="onco12239-li-0140"><p>Median (range): None</p></def></def-item><def-item><term id="onco12239-li-0141">Performance Status ECOG</term><def id="onco12239-li-0142"><p>0 &#x02014; 32</p><p>1 &#x02014; 32</p><p>2 &#x02014;</p><p>3 &#x02014;</p><p>Unknown &#x02014; 2</p></def></def-item><def-item><term id="onco12239-li-0151">Cancer Types or Histologic Subtypes</term><def id="onco12239-li-0152"><p>CA19&#x02010;9 levels &#x02264;90 U/mL 11</p><p>CA19&#x02010;9 levels &#x0003e;90 U/mL 54</p><p>CA19&#x02010;9 levels Unknown 1</p><p>Hsp27 expression high 11</p><p>Hsp27 expression low 47</p><p>Hsp27 expression Unknown 8</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0010"><title>Patient Characteristics for Phase II Experimental</title><p>
<def-list id="onco12239-lp-0005"><def-item><term id="onco12239-li-0163">Number of Patients, Male</term><def id="onco12239-li-0164"><p>37</p></def></def-item><def-item><term id="onco12239-li-0165">Number of Patients, Female</term><def id="onco12239-li-0166"><p>29</p></def></def-item><def-item><term id="onco12239-li-0167">Stage</term><def id="onco12239-li-0168"><p>IV</p></def></def-item><def-item><term id="onco12239-li-0169">Age</term><def id="onco12239-li-0170"><p>Median (range): 66.5 (39&#x02013;82)</p></def></def-item><def-item><term id="onco12239-li-0171">Number of Prior Systemic Therapies</term><def id="onco12239-li-0172"><p>Median (range): None</p></def></def-item><def-item><term id="onco12239-li-0173">Performance Status: ECOG</term><def id="onco12239-li-0174"><p>0 &#x02014; 30</p><p>1 &#x02014; 36</p><p>2 &#x02014;</p><p>3 &#x02014;</p><p>Unknown &#x02014;</p></def></def-item><def-item><term id="onco12239-li-0183">Cancer Types or Histologic Subtypes</term><def id="onco12239-li-0184"><p>CA19&#x02010;9 levels &#x02264;90 U/mL 18</p><p>CA19&#x02010;9 levels &#x0003e;90 U/mL 47</p><p>CA19&#x02010;9 levels unknown 1</p><p>Hsp27 expression high 7</p><p>Hsp27 expression low 55</p><p>Hsp27 expression unknown 4</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0011"><title>Primary Assessment Method for Phase II Control</title><p>
<def-list id="onco12239-lp-0006"><def-item><term id="onco12239-li-0195">Assessment: Total Patient Population: Overall Survival</term><def id="onco12239-li-0196"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0197">Number of patients screened</term><def id="onco12239-li-0198"><p>66</p></def></def-item><def-item><term id="onco12239-li-0199">Number of patients enrolled</term><def id="onco12239-li-0200"><p>66</p></def></def-item><def-item><term id="onco12239-li-0201">Number of patients evaluable for toxicity</term><def id="onco12239-li-0202"><p>63</p></def></def-item><def-item><term id="onco12239-li-0203">Number of patients evaluated for efficacy</term><def id="onco12239-li-0204"><p>66</p></def></def-item><def-item><term id="onco12239-li-0205">Evaluation method</term><def id="onco12239-li-0206"><p>RECIST 1.1</p></def></def-item><def-item><term id="onco12239-li-0207">Response assessment CR</term><def id="onco12239-li-0208"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12239-li-0209">Response assessment PR</term><def id="onco12239-li-0210"><p><italic>n</italic>&#x02009;=&#x02009;12 (18%)</p></def></def-item><def-item><term id="onco12239-li-0211">Response assessment SD</term><def id="onco12239-li-0212"><p><italic>n</italic>&#x02009;=&#x02009;21 (32%)</p></def></def-item><def-item><term id="onco12239-li-0213">Response assessment PD</term><def id="onco12239-li-0214"><p><italic>n</italic>&#x02009;=&#x02009;18 (28%)</p></def></def-item><def-item><term id="onco12239-li-0215">Response assessment OTHER</term><def id="onco12239-li-0216"><p><italic>n</italic>&#x02009;=&#x02009;15 (22%)</p></def></def-item><def-item><term id="onco12239-li-0217">(Median) duration assessments PFS</term><def id="onco12239-li-0218"><p>3.8 months</p></def></def-item><def-item><term id="onco12239-li-0219">(Median) duration assessments OS</term><def id="onco12239-li-0220"><p>6.9 months</p></def></def-item><def-item><term id="onco12239-li-8219">Kaplan&#x02010;Meier time units</term><def id="onco12239-li-7220"><p>months</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-1012"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><caption><p>Waterfall plot demonstrating best objective response in response&#x02010;evaluable subjects on control arm.</p></caption><graphic xlink:href="onco12239-fig-0001.jpg" position="anchor" id="nlm-graphic-3" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-1632"><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0002"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12239-sec-7512"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0002.jpg" position="anchor" id="nlm-graphic-9" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-0012"><title>Assessment: Total Patient Population: Progression&#x02010;Free Survival</title><p>
<def-list id="onco12239-lp-0007"><def-item><term id="onco12239-li-0221">Number of patients screened</term><def id="onco12239-li-0222"><p>66</p></def></def-item><def-item><term id="onco12239-li-0223">Number of patients enrolled</term><def id="onco12239-li-0224"><p>66</p></def></def-item><def-item><term id="onco12239-li-0225">Number of patients evaluable for toxicity</term><def id="onco12239-li-0226"><p>63</p></def></def-item><def-item><term id="onco12239-li-0227">Number of patients evaluated for efficacy</term><def id="onco12239-li-0228"><p>66</p></def></def-item><def-item><term id="onco12239-li-0229">Evaluation method</term><def id="onco12239-li-0230"><p>RECIST 1.1</p></def></def-item><def-item><term id="onco12239-li-0231">Response assessment CR</term><def id="onco12239-li-0232"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12239-li-0233">Response assessment PR</term><def id="onco12239-li-0234"><p><italic>n</italic>&#x02009;=&#x02009;12 (18%)</p></def></def-item><def-item><term id="onco12239-li-0235">Response assessment SD</term><def id="onco12239-li-0236"><p><italic>n</italic>&#x02009;=&#x02009;21 (32%)</p></def></def-item><def-item><term id="onco12239-li-0237">Response assessment PD</term><def id="onco12239-li-0238"><p><italic>n</italic>&#x02009;=&#x02009;18 (28%)</p></def></def-item><def-item><term id="onco12239-li-0239">Response assessment OTHER</term><def id="onco12239-li-0240"><p><italic>n</italic>&#x02009;=&#x02009;15 (22%)</p></def></def-item><def-item><term id="onco12239-li-0241">(Median) duration assessments PFS</term><def id="onco12239-li-0242"><p>3.8 months</p></def></def-item><def-item><term id="onco12239-li-0243">(Median) duration assessments OS</term><def id="onco12239-li-0244"><p>6.9 months</p></def></def-item><def-item><term id="onco12239-li-1243">Kaplan&#x02010;Meier time units</term><def id="onco12239-li-1244"><p>months</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-1112"><p>
<table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0003"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12239-sec-2392"><p>
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0003.jpg" position="anchor" id="nlm-graphic-15" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-0013"><title>Primary Assessment Method for Phase II Experimental</title><p>
<def-list id="onco12239-lp-0008"><def-item><term id="onco12239-li-0245">Assessment: Total Patient Population: Overall Survival</term><def id="onco12239-li-0246"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12239-li-0247">Number of patients screened</term><def id="onco12239-li-0248"><p>66</p></def></def-item><def-item><term id="onco12239-li-0249">Number of patients enrolled</term><def id="onco12239-li-0250"><p>66</p></def></def-item><def-item><term id="onco12239-li-0251">Number of patients evaluable for toxicity</term><def id="onco12239-li-0252"><p>64</p></def></def-item><def-item><term id="onco12239-li-0253">Number of patients evaluated for efficacy</term><def id="onco12239-li-0254"><p>66</p></def></def-item><def-item><term id="onco12239-li-0255">Evaluation method</term><def id="onco12239-li-0256"><p>RECIST 1.1</p></def></def-item><def-item><term id="onco12239-li-0257">Response assessment CR</term><def id="onco12239-li-0258"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12239-li-0259">Response assessment PR</term><def id="onco12239-li-0260"><p><italic>n</italic>&#x02009;=&#x02009;12 (18%)</p></def></def-item><def-item><term id="onco12239-li-0261">Response assessment SD</term><def id="onco12239-li-0262"><p><italic>n</italic>&#x02009;=&#x02009;16 (24%)</p></def></def-item><def-item><term id="onco12239-li-0263">Response assessment PD</term><def id="onco12239-li-0264"><p><italic>n</italic>&#x02009;=&#x02009;21 (32%)</p></def></def-item><def-item><term id="onco12239-li-0265">Response assessment OTHER</term><def id="onco12239-li-0266"><p><italic>n</italic>&#x02009;=&#x02009;17 (26%)</p></def></def-item><def-item><term id="onco12239-li-0267">(Median) duration assessments PFS</term><def id="onco12239-li-0268"><p>2.7 months</p></def></def-item><def-item><term id="onco12239-li-1269">(Median) duration assessments OS</term><def id="onco12239-li-1270"><p>5.3</p></def></def-item><def-item><term id="onco12239-li-1219">Kaplan-Meier time units</term><def id="onco12239-li-1220"><p>months</p></def></def-item></def-list>
</p></sec><sec id="onco12239-sec-1395"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><caption><p>Waterfall plot demonstrating best objective response in response&#x02010;evaluable subjects on experimental arm.</p></caption><graphic xlink:href="onco12239-fig-0004.jpg" position="anchor" id="nlm-graphic-19" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text>
</p></sec><sec id="onco12239-sec-5312"><p><table-wrap id="nlm-table-wrap-3" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-23" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0004"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12239-sec-5422"><p>
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0005.jpg" position="anchor" id="nlm-graphic-25" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-0014"><title>Assessment: Total Patient Population: Progression&#x02010;Free Survival</title><p>
<def-list id="onco12239-lp-0009"><def-item><term id="onco12239-li-0271">Number of patients screened</term><def id="onco12239-li-0272"><p>66</p></def></def-item><def-item><term id="onco12239-li-0273">Number of patients enrolled</term><def id="onco12239-li-0274"><p>66</p></def></def-item><def-item><term id="onco12239-li-0275">Number of patients evaluable for toxicity</term><def id="onco12239-li-0276"><p>64</p></def></def-item><def-item><term id="onco12239-li-0277">Number of patients evaluated for efficacy</term><def id="onco12239-li-0278"><p>66</p></def></def-item><def-item><term id="onco12239-li-0279">Evaluation method</term><def id="onco12239-li-0280"><p>RECIST 1.1</p></def></def-item><def-item><term id="onco12239-li-0281">Response assessment CR</term><def id="onco12239-li-0282"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12239-li-0283">Response assessment PR</term><def id="onco12239-li-0284"><p><italic>n</italic>&#x02009;=&#x02009;12 (18%)</p></def></def-item><def-item><term id="onco12239-li-0285">Response assessment SD</term><def id="onco12239-li-0286"><p><italic>n</italic>&#x02009;=&#x02009;16 (24%)</p></def></def-item><def-item><term id="onco12239-li-0287">Response assessment PD</term><def id="onco12239-li-0288"><p><italic>n</italic>&#x02009;=&#x02009;21 (32%)</p></def></def-item><def-item><term id="onco12239-li-0289">Response assessment OTHER</term><def id="onco12239-li-0290"><p><italic>n</italic>&#x02009;=&#x02009;17 (26%)</p></def></def-item><def-item><term id="onco12239-li-4219">Kaplan-Meier time units</term><def id="onco12239-li-4220"><p>months</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-2412"><p>
<table-wrap id="nlm-table-wrap-4" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-29" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0005"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12239-sec-6782"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0006.jpg" position="anchor" id="nlm-graphic-31" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-1014"><title>Adverse Events</title><p>
<table-wrap id="nlm-table-wrap-5" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-35" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0006"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12239-sec-0015"><title>Assessment, Analysis, and Discussion</title><p>
<def-list id="onco12239-lp-0010"><def-item><term id="onco12239-li-0291">Completion</term><def id="onco12239-li-0292"><p>Study completed</p></def></def-item><def-item><term id="onco12239-li-0293">Pharmacokinetics/Pharmacodynamics</term><def id="onco12239-li-0294"><p>Correlative endpoints not met</p></def></def-item><def-item><term id="onco12239-li-0295">Investigator's Assessment</term><def id="onco12239-li-0296"><p>Feasible, possibly effective in patients with high Hsp27 serum levels</p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0016"><p>Pancreatic adenocarcinoma is expected to rise to the second leading cause of cancer&#x02010;related mortality in the U.S. by the end of this decade [<xref rid="onco12239-bib-0009" ref-type="ref">9</xref>]. Systemic therapy represents the mainstay of treatment for patients with advanced or metastatic disease, for whom two combination chemotherapy regimens have emerged as front&#x02010;line standards of care: gemcitabine plus nab&#x02010;paclitaxel [<xref rid="onco12239-bib-0008" ref-type="ref">8</xref>], and FOLFIRINOX (5&#x02010;fluorouracil, leucovorin, irinotecan, and oxaliplatin) [<xref rid="onco12239-bib-0010" ref-type="ref">10</xref>]. However, despite these recent improvements in available cytotoxic therapies, overall prognosis in this disease remains very poor; for example, in the phase III MPACT trial leading to the approval of nab&#x02010;paclitaxel for metastatic pancreatic cancer, the median survival for patients receiving the combination of gemcitabine plus nab&#x02010;paclitaxel was only 8.5 months, representing a statistically significant but relatively modest absolute improvement of 1.8 months when compared with single&#x02010;agent gemcitabine [<xref rid="onco12239-bib-0008" ref-type="ref">8</xref>]. Clearly, novel drugs with unique mechanisms of action warrant further exploration.</p><p>Molecularly targeted therapies that have been approved for use in clinical oncology include monoclonal antibodies and small molecule inhibitors, particularly tyrosine kinase inhibitors. Unfortunately, many potential therapeutic targets are not amenable to these specific pharmacologic approaches, highlighting the importance of developing alternative strategies, including agents that can disrupt these targets at the gene expression level. Antisense oligonucleotides (ASOs), which are chemically modified stretches of single&#x02010;strand DNA complementary to the mRNA regions of a target gene that inhibit translation by forming RNA/DNA duplexes, represent one such approach to specifically prevent translation of functionally relevant genes.</p><p>Apatorsen, a 2&#x02019;&#x02010;methoxyethyl oligonucleotide with phosphorothiolated internucleotide linkages, is designed to bind to heat shock protein 27 (Hsp27) mRNA and prevent translation into a functional protein. Targeting this specific heat shock protein represents an attractive therapeutic option, because Hsp27 can potentially affect multiple pathways implicated in cancer progression and resistance, as opposed to targeting a single pathway, a strategy that might have limited benefits in the face of the redundant signaling pathways and significant tumor heterogeneity. For example, overexpression of Hsp27 in cancer cells is induced by cytotoxic chemotherapy, as well as other cell stressors including hyperthermia, oxidative stress, and radiation, resulting in cytoprotection against these insults [<xref rid="onco12239-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12239-bib-0002" ref-type="ref">2</xref>]. Furthermore, Hsp27 serves to stabilize mutated or inappropriately activated oncoproteins that contribute to the initiation, growth, and metastasis of human cancers [<xref rid="onco12239-bib-0002" ref-type="ref">2</xref>], [<xref rid="onco12239-bib-0011" ref-type="ref">11</xref>].</p><p>The phase I dose&#x02010;escalation study of apatorsen in patients with castration&#x02010;resistant prostate cancer and other advanced cancers showed evidence of monotherapy activity as demonstrated by decline in tumor markers and circulating tumor cells, as well as stable measurable disease in 12 of 42 patients [<xref rid="onco12239-bib-0012" ref-type="ref">12</xref>]. Further evaluation of apatorsen has been pursued in combination with chemotherapeutic agents in clinical trials specific to non&#x02010;small cell lung and bladder cancer [<xref rid="onco12239-bib-0013" ref-type="ref">13</xref>], [<xref rid="onco12239-bib-0014" ref-type="ref">14</xref>].</p><p>Pancreatic adenocarcinomas show higher levels of Hsp27 expression when compared with healthy pancreatic tissue, and the protein can also be detected with high sensitivity in the serum of patients with pancreatic cancer [<xref rid="onco12239-bib-0003" ref-type="ref">3</xref>]. Preclinical studies additionally show that Hsp27 expression may play a role in the resistance of pancreatic cancer cell lines to gemcitabine [<xref rid="onco12239-bib-0004" ref-type="ref">4</xref>], [<xref rid="onco12239-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12239-bib-0006" ref-type="ref">6</xref>]. On these bases, the current study was designed to compare the safety and efficacy of gemcitabine and nab&#x02010;paclitaxel in combination with either apatorsen or placebo in the first&#x02010;line setting for patients with metastatic pancreatic cancer. However, we did not observe any improvement in clinical outcomes in the intent&#x02010;to&#x02010;treat population in this trial; indeed, patients on the apatorsen arm fared numerically worse in terms of both PFS and OS when compared with patients on the placebo control arm, although these differences were not statistically significant. The only subgroup for whom a potential benefit of apatorsen could be identified was those patients with high serum levels of Hsp27, a marker that portended a very poor prognosis overall. However, the number of subjects who fit into this category was too small, representing only 14% of the entire study population, to draw any definitive conclusions. Further studies, either prospectively designed trials or retrospective analyses of available clinically annotated samples, will be required to assess whether Hsp27 truly represents an adverse prognostic marker in this disease.</p><p>Several additional points are worth noting. First, the clinical outcomes for patients on both arms of this study were considerably inferior to those observed on the gemcitabine plus nab&#x02010;paclitaxel arm from the phase III MPACT trial [<xref rid="onco12239-bib-0008" ref-type="ref">8</xref>], in which patients achieved a median OS and PFS of 8.5 and 5.5 months, respectively. It is unclear why subjects on the current study fared so poorly, given similar demographics to the MPACT study; nevertheless, it seems fairly unlikely that a benefit from apatorsen would somehow be unmasked even if patients had achieved outcomes that more similarly matched those of the MPACT trial. Furthermore, because this study did not mandate pretreatment collection of tumor specimens, putative tissue&#x02010;based predictive markers of apatorsen sensitivity could not be assessed, nor could the pharmacodynamic effects of this agent given the absence of requiring on&#x02010;treatment tumor biopsies. No consistent trend was identified on serial serum Hsp27 measurements in responders versus nonresponders (data not shown). This lack of robust correlative data represents a major limitation of our study and highlights one of the major ongoing challenges in pancreatic cancer trial design in general, especially when trying to confirm the putative mechanism of action of novel targeted agents.</p><p>In conclusion, the addition of apatorsen to a standard combination chemotherapy regimen in the first&#x02010;line setting did not result in improved survival or other clinically relevant endpoints in patients with metastatic pancreatic cancer. Further studies of this agent in unselected patients do not appear to be indicated, although the findings from this trial do hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation. If ASO technologies targeting this and other cancer&#x02010;related genes continue to be pursued in pancreatic cancer, they should ideally be evaluated in the context of trials that mandate serial collection of both tumor and blood samples to look for predictive markers and pharmacodynamic markers of response, notwithstanding the clinical and logistic hurdles these may present in this patient population.</p></sec></body><back><ack id="onco12239-sec-0017"><title>Acknowledgments</title><p>This work was supported in part by a grant from OncoGenex Pharmaceuticals, Inc.</p></ack><fn-group><fn fn-type="other" id="onco12239-note-1201"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01844817">NCT01844817</ext-link></p><p><bold>Sponsor</bold>: Sarah Cannon Research Institute</p><p><bold>Principal Investigators</bold>: Andrew H. Ko, Johanna C. Bendell</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12239-note-4392"><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p></fn><fn id="onco12239-note-0102"><p>See the related commentary on page <ext-link ext-link-type="doi" xlink:href="10.1634/theoncologist.2017-0453">1424</ext-link>.</p></fn></fn-group><sec id="onco12239-sec-0018" sec-type="disclosure"><title>Disclosures</title><p><bold>Andrew H. Ko</bold>: Seattle Genetics, New Beta Innovations (C/A), Merck, Bristol&#x02010;Myers Squibb, Abgenomics, Prism Bio Ltd, Merrimack, Halozyme, Celgene, Roche/Genentech (RF); <bold>David M. Waterhouse</bold>: Bristol&#x02010;Myers Squibb, ABBVie (H). The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12239-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12239-cit-0001">
<string-name><surname>Garrido</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Brunet</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Didelot</surname>
<given-names>C</given-names></string-name> et al. <article-title>Heat shock proteins 27 and 70: Anti&#x02010;apoptotic proteins with tumorigenic properties</article-title>. <source>Cell Cycle</source>
<year>2006</year>;<volume>5</volume>:<fpage>2592</fpage>&#x02013;<lpage>2601</lpage>.
<pub-id pub-id-type="pmid">17106261</pub-id></mixed-citation></ref><ref id="onco12239-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12239-cit-0002">
<string-name><surname>Ciocca</surname>
<given-names>DR</given-names></string-name>, 
<string-name><surname>Calderwood</surname>
<given-names>SK.</given-names></string-name>
<article-title>Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications</article-title>. <source>Cell Stress Chaperones</source>
<year>2005</year>;<volume>10</volume>:<fpage>86</fpage>&#x02013;<lpage>103</lpage>.
<pub-id pub-id-type="pmid">16038406</pub-id></mixed-citation></ref><ref id="onco12239-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12239-cit-0003">
<string-name><surname>Melle</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Ernst</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Escher</surname>
<given-names>N</given-names></string-name> et al. <article-title>Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker</article-title>. <source>Clin Chem</source>
<year>2007</year>;<volume>53</volume>:<fpage>629</fpage>&#x02013;<lpage>635</lpage>.
<pub-id pub-id-type="pmid">17303689</pub-id></mixed-citation></ref><ref id="onco12239-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12239-cit-0004">
<string-name><surname>Kuramitsu</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Taba</surname>
<given-names>K</given-names></string-name> et al. <article-title>Heat&#x02010;shock protein 27 plays the key role in gemcitabine&#x02010;resistance of pancreatic cancer cells</article-title>. <source>Anticancer Res</source>
<year>2012</year>;<volume>32</volume>:<fpage>2295</fpage>&#x02013;<lpage>2299</lpage>.
<pub-id pub-id-type="pmid">22641665</pub-id></mixed-citation></ref><ref id="onco12239-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12239-cit-0005">
<string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Zhang</surname>
<given-names>XQ</given-names></string-name>, 
<string-name><surname>Huang</surname>
<given-names>SL</given-names></string-name> et al. <article-title>The effects of HSP27 on gemcitabine&#x02010;resistant pancreatic cancer cell line through snail</article-title>. <source>Pancreas</source>
<year>2015</year>;<volume>44</volume>:<fpage>1121</fpage>&#x02013;<lpage>1129</lpage>.
<pub-id pub-id-type="pmid">26348464</pub-id></mixed-citation></ref><ref id="onco12239-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12239-cit-0006">
<string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Ziesch</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Hocke</surname>
<given-names>S</given-names></string-name> et al. <article-title>Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S&#x02010;phase arrest and apoptosis</article-title>. <source>J Cell Mol Med</source>
<year>2015</year>;<volume>19</volume>:<fpage>340</fpage>&#x02013;<lpage>350</lpage>.
<pub-id pub-id-type="pmid">25331547</pub-id></mixed-citation></ref><ref id="onco12239-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12239-cit-0007">
<string-name><surname>Kamada</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>So</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Muramaki</surname>
<given-names>M</given-names></string-name> et al. <article-title>Hsp27 knockdown using nucleotide&#x02010;based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells</article-title>. <source>Mol Cancer Ther</source>
<year>2007</year>;<volume>6</volume>:<fpage>299</fpage>&#x02013;<lpage>308</lpage>.
<pub-id pub-id-type="pmid">17218637</pub-id></mixed-citation></ref><ref id="onco12239-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12239-cit-0008">
<string-name><surname>Von Hoff</surname>
<given-names>DD</given-names></string-name>, 
<string-name><surname>Ervin</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Arena</surname>
<given-names>FP</given-names></string-name> et al. <article-title>Increased survival in pancreatic cancer with nab&#x02010;paclitaxel plus gemcitabine</article-title>. <source>N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>1691</fpage>&#x02013;<lpage>1703</lpage>.
<pub-id pub-id-type="pmid">24131140</pub-id></mixed-citation></ref><ref id="onco12239-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12239-cit-0009">
<string-name><surname>Rahib</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Smith</surname>
<given-names>BD</given-names></string-name>, 
<string-name><surname>Aizenberg</surname>
<given-names>R</given-names></string-name> et al. <article-title>Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States</article-title>. <source>Cancer Res</source>
<year>2014</year>;<volume>74</volume>:<fpage>2913</fpage>&#x02013;<lpage>2921</lpage>.
<pub-id pub-id-type="pmid">24840647</pub-id></mixed-citation></ref><ref id="onco12239-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12239-cit-0010">
<string-name><surname>Conroy</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Desseigne</surname>
<given-names>F</given-names></string-name>, 
<string-name><surname>Ychou</surname>
<given-names>M</given-names></string-name> et al. <article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source>N Engl J Med</source>
<year>2011</year>;<volume>364</volume>:<fpage>1817</fpage>&#x02013;<lpage>1825</lpage>.
<pub-id pub-id-type="pmid">21561347</pub-id></mixed-citation></ref><ref id="onco12239-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12239-cit-0011">
<string-name><surname>Acunzo</surname>
<given-names>J</given-names></string-name>, 
<string-name><surname>Andrieu</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Baylot</surname>
<given-names>V</given-names></string-name> et al. <article-title>Hsp27 as a therapeutic target in cancers</article-title>. <source>Curr Drug Targets</source>
<year>2014</year>;<volume>15</volume>:<fpage>423</fpage>&#x02013;<lpage>431</lpage>.
<pub-id pub-id-type="pmid">24138636</pub-id></mixed-citation></ref><ref id="onco12239-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12239-cit-0012">
<string-name><surname>Chi</surname>
<given-names>KN</given-names></string-name>, 
<string-name><surname>Yu</surname>
<given-names>EY</given-names></string-name>, 
<string-name><surname>Jacobs</surname>
<given-names>C</given-names></string-name> et al. <article-title>A phase I dose&#x02010;escalation study of apatorsen (OGX&#x02010;427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration&#x02010;resistant prostate cancer and other advanced cancers</article-title>. <source>Ann Oncol</source>
<year>2016</year>;<volume>27</volume>:<fpage>1116</fpage>&#x02013;<lpage>1122</lpage>.
<pub-id pub-id-type="pmid">27022067</pub-id></mixed-citation></ref><ref id="onco12239-bib-0013"><label>13</label><mixed-citation publication-type="book" id="onco12239-cit-0013">
<string-name><surname>Choueiri</surname>
<given-names>TK</given-names></string-name>, 
<string-name><surname>Hahn</surname>
<given-names>NM</given-names></string-name>, 
<string-name><surname>Pal</surname>
<given-names>SK</given-names></string-name> et al. <chapter-title>The Borealis&#x02010;2 clinical trial: A randomized phase 2 study of OGX&#x02010;427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer</chapter-title>
<source>J Clin Oncol</source>
<year>2014</year>;<publisher-name>32</publisher-name>(suppl):<fpage>TPS4593a</fpage>.
</mixed-citation></ref><ref id="onco12239-bib-0014"><label>14</label><mixed-citation publication-type="book" id="onco12239-cit-0014">
<string-name><surname>Spigel</surname>
<given-names>DR</given-names></string-name>, 
<string-name><surname>Burris</surname>
<given-names>HA</given-names></string-name>, 
<string-name><surname>Greco</surname>
<given-names>FA</given-names></string-name> et al. <chapter-title>Double&#x02010;blind randomized phase II trial of carboplatin and pemetrexed with or without OGX&#x02010;427 in patients with previously untreated stage IV non&#x02010;squamous non&#x02010;small&#x02010;cell lung cancer (NSCLC): The Spruce Clinical Trial</chapter-title>
<source>J Clin Oncol</source>
<year>2013</year>;31(suppl):<fpage>TPS8120a</fpage>.
</mixed-citation></ref></ref-list></back></article>